Screener
AnaptysBio, Inc. ANAB Biopharma Company — Interest Income Other
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by AnaptysBio, Inc. in its filing.
Tagged under the XBRL concept us-gaap:InterestIncomeOther.
The source filing: AnaptysBio, Inc.’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 4:20 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-219515
| Line item | Biopharma | Royalty Management | Total |
|---|---|---|---|
| Total G&A | 18,856 | 7,346 | 26,202 |
| Total operating expenses | 52,811 | 7,382 | 60,193 |
| (Loss) income from operations | (52,811) | 18,174 | (34,637) |
| Interest income | 2,328 | 325 | 2,653 |
| Non-cash interest expense | — | (20,859) | (20,859) |
| Other expense, net | (1) | — | (1) |
| Total other income (expense), net | 2,327 | (20,534) | (18,207) |
| Loss before income taxes | (50,484) | (2,360) | (52,844) |
Item 1. Consolidated Financial Statements
FAQ
- What is AnaptysBio, Inc.'s biopharma company — interest income other?
- AnaptysBio, Inc. (ANAB) reported biopharma company — interest income other of $2.33M in Q1 2026.
- How has AnaptysBio, Inc.'s biopharma company — interest income other changed year-over-year?
- AnaptysBio, Inc.'s biopharma company — interest income other decreased by 43.1% year-over-year, from $4.09M to $2.33M.
- What does biopharma company — interest income other mean?
- This metric represents the income generated from the company's cash, cash equivalents, and marketable securities. It reflects the yield on the company's treasury management and liquid assets. For pre-revenue companies, this income can partially offset operating expenses and extend the company's cash runway.
Ask your AI about AnaptysBio, Inc.'s biopharma company — interest income other.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude